<?xml version="1.0" encoding="UTF-8"?>
<ref id="B66-pharmaceuticals-13-00464">
 <label>66.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Khan</surname>
    <given-names>M.S.S.</given-names>
   </name>
   <name>
    <surname>Asif</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Basheer</surname>
    <given-names>M.K.A.</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>C.W.</given-names>
   </name>
   <name>
    <surname>Al-Suede</surname>
    <given-names>F.S.</given-names>
   </name>
   <name>
    <surname>Ein</surname>
    <given-names>O.C.</given-names>
   </name>
   <name>
    <surname>Tang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Majid</surname>
    <given-names>A.S.A.</given-names>
   </name>
   <name>
    <surname>Majid</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Treatment of novel IL17A inhibitor in glioblastoma implementing 3rd generation co-culture cell line and patient-derived tumor model</article-title>
  <source>Eur. J. Pharm.</source>
  <year>2017</year>
  <volume>803</volume>
  <fpage>24</fpage>
  <lpage>38</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejphar.2017.03.031</pub-id>
 </element-citation>
</ref>
